Expert Perspectives: Q&A on Actemra’s phase 3 EMPACTA study
In the first of an ongoing series of “Expert Perspectives” with members of inDemic Foundation’s scientific advisory board, we discuss data from EMPACTA, a randomized, double-blind, placebo-controlled phase 3 trial evaluating the efficacy and safety of Roche’s Actemra (tocilizumab) in hospitalized patients with COVID-19 pneumonia (NCT04372186). Actemra is one of several IL-6 inhibitors that’s been evaluated for patients with COVID-19. At the time of this writing, data from EMPACTA has not been published in a peer-reviewed journal, but some of its key findings have been released by Roche/Genentech.